EL.En. (ELN) Q2 2026 earnings summary

Executive summary

• Revenues for H1 2026 reached €246.5 million, up 9.1% year-over-year, driven by strong medical sector growth and the strategic divestment of the laser cutting business, which now brings the medical sector to 92% of revenue.

• EBIT rose 37.6% to €43.4 million, and net income increased 45.5% to €26.1 million, reflecting improved margins and operational leverage.

• The sale of the majority stake in the laser cutting division to TRUMPF was finalized or is expected to close soon, further concentrating operations on medical applications.

• Net financial position improved by €12 million to €184.5 million as of June 2026, despite dividend payments and investments.

• The group is focused on R&D and innovation in medical devices, particularly in anti-aging and surgical applications.

Financial highlights

• Medical segment revenues grew 10.4% year-over-year to €227.5 million, now 92.3% of total revenue.

• Gross margin rose 12.4% to €122.8 million, with margin at 49.8% of revenue.

• EBITDA increased 30% to €48.7 million, with margin up to 19.8% from 16.6% year-over-year.

• EBIT margin increased to 17.6% from 14.0% year-over-year.

• Net equity rose 1.9% to €435.6 million.

Outlook and guidance

• Guidance confirmed for FY 2026: revenue growth over 5% and improved EBIT margin, achievable even after the disposal of the laser cutting business.

• Strong H2 expected, with medical segment performance set to offset the absence of the cutting division.

• Management expresses confidence in sustainable, profitable growth focused on the medical sector.

• No major M&A planned; focus remains on organic growth and selective bolt-on acquisitions.